Navigation Links
ExonHit Completes a Prototype to Detect Alzheimer's Disease From Blood
Date:11/8/2007

t patients suffering from other dementias such as frontal lobe dementias, Lewy body dementias or vascular dementias. This will be validated in mid-2008, after we have compared our signature to the clinical diagnostic criterias for these dementias" declared Laurent Bracco, Executive Vice President for Research at ExonHit Therapeutics.

"We are making good progress towards having our first diagnostic certified. We will be able to provide it as a service in Europe and in the USA, to companies interested in recruiting patients with a specific blood signature, as well as meeting the current recruitment criteria" stated Bruno Tocque, President of the Management Board of ExonHit. He added "There are approximately 140 clinical trials ongoing in Alzheimer's disease. This is an ideal market for ExonHit".

About ExonHit Therapeutics

http://www.exonhit.com

ExonHit Therapeutics is the world's leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases.

ExonHit has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays, SpliceArray(TM) family of products that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers and develops its own projects for the detection of other chronic diseases such as Alzheimer's disease or atherosclerosis.

In parallel, ExonHit is developing its own therapeutic pipeline in the field of neurodegenerative diseases an
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
2. H2Diesel Completes 3 Million Gallon Per Year Pilot Facility
3. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Carrington Completes $8 Million Financing
6. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
7. New Brunswick Scientific Completes Merger Transaction with Eppendorf
8. Kiwa Bio-Tech Completes 1st Stage of Shandong Factory Upgrading
9. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
10. Optherion, Inc. Completes $37 Million Start Up Financing
11. Companys Partner Completes Trial Production of a New Antiviral Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ... July 03, 2015 , ... Cuvettes have been used in countless labs for decades. ... the cuvette they needed. As expected, this was a daunting and tiring process looking ... because they were not able to navigate the complex catalog structure. , Now thanks to ...
(Date:7/2/2015)... -- Amici Procurement Migrates to the Cloud ... has chosen Microsoft Cloud Solution Provider iomart ...      (Logo: http://photos.prnewswire.com/prnh/20121126/579634) , ... the bio-tech sector with a unique procurement service, helping ... help them obtain best value. Its IT platform hosts ...
(Date:7/1/2015)... ... July 01, 2015 , ... It is now possible to separate two common ... emission computed tomography (SPECT) according to researchers from Amen Clinics, UCLA, Thomas Jefferson ... scans and is believed to be the largest brain imaging study ever, will be ...
(Date:7/1/2015)... ... ... The next-generation sequencing (NGS) clinical market is poised for huge growth as ... Research reveals in its new report that the market drivers of this vibrant industry ... for better diagnostics as part of a molecular diagnostics trend. , The global market ...
Breaking Biology Technology:New Cuvette E-Commerce Website Launched by FireflySci 2Biotech Procurement Company Moves to Office 365 with iomart 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3
... SALES INCREASE 14.6%. Q4 2007 DILUTED EPS UP 20.8% TO $.64. 2008 ... - $2.62 PER SHARE., ST. LOUIS, Feb. 12 , ... -- Q4 2007 Sales Set New Quarterly Record: At ... quarterly high, beating the Q2 2007 record of ...
... Inc. (Nasdaq: NSTK ) announced today that ... further reduce operating expenses and,align the company,s workforce ... "The workforce reduction of approximately 50 employees will ... RNAi programs forward in a more,efficient manner for ...
... 12, Shire plc (LSE: SHP)(NASDAQ: SHPGY )(TSX: SHQ),the ... on Thursday 21 February 2008., Results press ... GMT / 07:00 EST Investor meeting and conference ... Investor & Analyst meeting and conference call:, Matthew ...
Cached Biology Technology:Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 2Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 3Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 4Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 5Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 6Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 7Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 8Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 9Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 10Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 11Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 12Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 13Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 14Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 15Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 16Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 17Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 18Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 19Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 20Nastech Pharmaceutical Company Implements Additional Workforce Reduction as Part of Previously Announced Corporate Restructuring 2Full Year 2007 Results Date Notification - 21 February 2008 2
(Date:6/25/2015)... According to a new ... Area), Technology, Material (Optical Prism, Piezoelectric, Capacitive & ... Others) & Geography - Global Forecast to 2014 ... is expected to reach $14,500.07 Million by 2020, ... Browse 76 market Tables and 109 Figures spread ...
(Date:6/24/2015)... , June 24, 2015 The biologics safety ... major drivers for the market include growth of the ... new drug launches. Over the years, the number of ... 2001 and 2010, the FDA approved 225 drug applications ... WIPO, Europe accounted for 3,822 ...
(Date:6/24/2015)... Research and Markets( ... "Huawei Ascend Mate 7 Fingerprint Sensor - ... Huawei,s technological choice for the fingerprint ... Apple,s and Samsung,s one. The Ascend Mate 7 ... Cards, a main actor in capacitive sensing human ...
Breaking Biology News(10 mins):Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
... at North Carolina State University is leading to a ... and harvested from freshwater ponds, instead of from the ... the pond-raised crabs look and taste just like their ... has been at historic lows since 2000. Dr. Dave ...
... victory and the dread of defeat whether in money, ... according to a new imaging study. Neuroscientists at the ... with competing responses to risk. Both regions are located ... in analysis and planning. By giving volunteers a ...
... can,t raise a finger without your brain directing muscle cells, ... so well. A neuron sends a message, or neurotransmitter, ... To get the message, the receiving cell must have a ... the receptor so it,s properly positioned to catch the message. ...
Cached Biology News:Turning freshwater farm ponds into crab farms 2Risk and reward compete in brain 2Stabilizing force for good communication between neurons and muscle cells found 2
Mouse monoclonal [B314.1 (MAC 387)] to Macrophage L1 protein Calprotectin (rating: ****) ( Abpromise for all tested applications)....
BAI-1 (T-20)...
Contained in EZ-Tn5™ Kits and are available separately for sequencing of an insertion site....
... peptide derived from the N-terminal region of ... Specificity: Specific for the N-terminus of the ... Dog Rat Mouse (positive controls: MDCK-II A431 ... heart blood vessel and brain mossy fiber ...
Biology Products: